Codexis (CDXS) Cost of Revenue (2010 - 2026)
Codexis (CDXS) recorded quarterly Cost of Revenue of $2.1 million in Q1 2026, up 1.03% quarter-over-quarter from $2.0 million in Q4 2025, and down 24.45% on a YoY basis from $2.7 million in Q1 2025.
Codexis (CDXS) Cost of Revenue (2010 - 2026) Analysis & Trends
Codexis' Cost of Revenue history runs 17 years deep, the most recent figure standing at $2.1 million for Q1 2026.
- In Q1 2026, Cost of Revenue fell 24.45% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $8.7 million (down 38.79% YoY), while the FY2025 annual figure was $9.3 million, down 42.67% from the prior year.
- Cost of Revenue was $2.1 million for Q1 2026 at Codexis, up from $2.0 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $11.3 million in Q2 2022 to a low of $2.0 million in Q4 2025.
- Historically, Cost of Revenue has averaged $4.6 million across 5 years, with a median of $3.5 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Cost of Revenue surged 161.0% in 2022, then sank 77.02% in 2023.
- A 5-year view of Cost of Revenue shows it stood at $8.5 million in 2022, then slumped by 66.15% to $2.9 million in 2023, then increased by 27.67% to $3.7 million in 2024, then tumbled by 44.09% to $2.0 million in 2025, then grew by 1.03% to $2.1 million in 2026.
- The last three Cost of Revenue figures came in at $2.1 million (Q1 2026), $2.0 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 2.05 Mn |
| 10 | Codexis | 236.00 Mn | 170.86 Mn | 13.18 Mn | 2.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.06 Mn |
| Mar 31, 2026 | 2.06 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Sep 30, 2025 | 2.47 Mn |
| Sep 30, 2025 | 2.47 Mn |
| Jun 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | 2.10 Mn |
| Mar 31, 2025 | 2.73 Mn |
| Mar 31, 2025 | 2.73 Mn |
| Dec 31, 2024 | 3.65 Mn |
| Dec 31, 2024 | 3.65 Mn |
| Sep 30, 2024 | 4.32 Mn |
| Sep 30, 2024 | 4.32 Mn |
| Jun 30, 2024 | 3.46 Mn |
| Jun 30, 2024 | 3.46 Mn |
| Mar 31, 2024 | 4.86 Mn |
| Mar 31, 2024 | 4.86 Mn |
| Dec 31, 2023 | 2.86 Mn |
| Dec 31, 2023 | 2.86 Mn |